

August 2, 2016



# VolitionRx Engages Edison Advisors as Investor Relations Counsel

NAMUR, Belgium, Aug. 2, 2016 /PRNewswire/ --[VolitionRx Limited](#) (NYSE MKT: VNRX), today announced that it has retained Edison Advisors, a global strategic advisory firm, as the Company's investor relations counsel.

Edison Advisors has been engaged to support, strategize, and execute a comprehensive investor relations strategy as VolitionRx prepares for the commercial launch of its NuQ<sup>®</sup> blood-based colorectal cancer test in Europe, expected later this year. A core focus of the engagement is to enhance VolitionRx's exposure, strengthen relationships, and facilitate investor communications and corporate access among global investment communities.

Cameron Reynolds, Chief Executive Officer of VolitionRx, stated, "As we transition to a commercial business with an international reach, engaging Edison Advisors is an important strategic decision to strengthen relationships with our stockholders and prospective investors. With extensive institutional investor contacts in North America and in Europe, they are the ideal partner aligned with our vision to reach a broader global investor audience. We would like to thank our previous advisors at The Ruth Group for all their hard work over the past 2 years."

Peter Molloy, Chief Executive Officer of Edison Group, North America, added, "We pride ourselves at Edison with our deep sector expertise which we use to support our extensive client base with both advisory services and investment research. We offer a truly global solution for our clients from our offices in North America, Europe and Asia-Pacific. We are delighted to have been selected by VolitionRx as one of their trusted advisors and we look forward to working with them and contributing to their success."

Results from clinical trials to date demonstrating the effectiveness of VolitionRx's NuQ<sup>®</sup> biomarker assays include:

## *Colorectal cancer and pre-cancerous colorectal adenomas*

- Interim results from a 4,800 patient retrospective symptomatic population study (Hvidovre Hospital, University of Copenhagen, Denmark), released September 9, 2015: Panel of four NuQ<sup>®</sup> biomarker assays detected 81% of colorectal cancers at 78% specificity and 67% of high-risk adenomas. For more information [click here](#).
- Results from a completed prospective study of 121 patients referred for colonoscopy (CHU Dinant Godinne - UCL Namur, in Belgium), released December 8, 2015: Panel of four NuQ<sup>®</sup> biomarker assays detected 91% of colorectal cancer cases at 90% specificity and also detected 67% of high-risk adenomas. For more information [click here](#).
- Results from a retrospective study of 430 patients referred for colonoscopy (Hvidovre Hospital, University of Copenhagen, Denmark), released February 17, 2016: Panel of

five NuQ<sup>®</sup> biomarker assays demonstrated 75% accuracy in detecting highest-risk pre-cancerous colorectal adenomas and also detected 86% of early (stage I) colorectal cancers at 78% specificity. For more information [click here](#).

### *Pancreatic cancer*

- Results from a 59-patient retrospective study (Lund University, Sweden) published in Clinical Epigenetics online journal (<http://www.clinicalepigeneticsjournal.com/content/pdf/s13148-015-0139-4.pdf>), October 7, 2015: Panel of four NuQ<sup>®</sup> biomarker assays plus CA 19-9 classical biomarker detected 92% of pancreatic cancers at 100% specificity. For more information [click here](#).
- Interim results from a 4,800 patient retrospective symptomatic population study (Hvidovre Hospital, University of Copenhagen, Denmark), released October 22, 2015: Panel of two NuQ<sup>®</sup> biomarker assays and the classical cancer marker CEA (carcino-embryonic antigen) detected 95% of pancreatic cancers at 84% specificity. For more information [click here](#).

### *Prostate Cancer*

- Results from a 537-patient retrospective study (Surrey Cancer Research Institute at University of Surrey, United Kingdom), released April 20, 2016 at the AACR Annual Meeting: A single NuQ<sup>®</sup> biomarker assay detected 71% of early stage I prostate cancer cases and 86% of late stage IV prostate cancer at 93% specificity, which is significantly higher than the commonly-used PSA test reported to detect 53% of prostate cancers at 73% specificity. For more information [click here](#).

### *Lung cancer*

- Interim results (73 of 240 patients collected and assessed) from a prospective study (Liège University Hospital, Belgium), released November 19, 2015: Panel of four NuQ<sup>®</sup> biomarker assays detected 93% of lung cancers at 91% specificity and differentiated lung cancer from the common lung disease, COPD. For more information [click here](#).

## **About VolitionRx**

VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics<sup>®</sup>, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

Visit VolitionRx's website (<http://www.volitionrx.com>) or connect with us via [Twitter](#), [LinkedIn](#), [Facebook](#) or [YouTube](#).

## About Edison Group

Edison, founded in 2003, is a strategic advisory and investment research company. We service 450 corporate clients with Investor Relations, Investment Research and Strategic Consulting from our offices in North America, Europe and Asia. Edison's renowned international investment research platform enables us to provide a highly differentiated approach to strategic advisory work based on deep multi-sector knowledge and extensive networks of investors, advisors and companies.

## Media / Investor Contacts

Louise Day, VolitionRx <a href="mailto:L.Day@volitionrx.com">L.Day@volitionrx.com</a> +44 (0)7557 774 620 Tirth Patel, Edison Advisors <a href="mailto:tpatel@edisongroup.com">tpatel@edisongroup.com</a> +1 (646) 653-7035	Scott Powell, VolitionRx <a href="mailto:S.Powell@volitionrx.com">S.Powell@volitionrx.com</a> +1 (646) 650-1351 Katherine Fennell, Edison Advisors <a href="mailto:kfennell@edisongroup.com">kfennell@edisongroup.com</a> +44 (0) 20 7841 1556
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics<sup>®</sup>, NuQ<sup>®</sup> and HyperGenomics<sup>®</sup> and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

SOURCE VolitionRx Ltd